Thromboxane production in morbidly obese subjects.

[1]  V. Basevi.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[2]  F. Crea,et al.  Paradoxical preservation of vascular function in severe obesity. , 2010, The American journal of medicine.

[3]  B. Chong,et al.  Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. , 2010, Heart, lung & circulation.

[4]  E. Grove,et al.  A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease , 2010, Thrombosis and Haemostasis.

[5]  C. Lavie,et al.  Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. , 2009, Journal of the American College of Cardiology.

[6]  F. Crea,et al.  COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. , 2009, European heart journal.

[7]  A. Carter,et al.  Elevated C-Reactive Protein and Long-Term Mortality After Ischaemic Stroke: Relationship With Markers of Endothelial Cell and Platelet Activation , 2009, Stroke.

[8]  G. Hasenfuss,et al.  Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity , 2008, Thrombosis and Haemostasis.

[9]  A. Corsonello,et al.  Leptin, obesity and platelet responsiveness: another piece in the puzzle. , 2008, Thrombosis and haemostasis.

[10]  M. Reilly,et al.  Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. , 2008, Journal of the American College of Cardiology.

[11]  L. Bortolotto,et al.  Systemic Inflammation and Cardiovascular Risk Factors: Are Morbidly Obese Subjects Different? , 2008, Obesity surgery.

[12]  G. Rossi,et al.  Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.

[13]  A. Saitta,et al.  Relationship between metabolic syndrome and platelet responsiveness to leptin in overweight and obese patients , 2007, International Journal of Obesity.

[14]  M. Lopes,et al.  Postmortem findings in morbidly obese individuals dying after gastric bypass procedures. , 2007, Human pathology.

[15]  F. Santilli,et al.  Insulin resistance as a determinant of platelet activation in obese women. , 2006, Journal of the American College of Cardiology.

[16]  M. Laposata,et al.  Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. , 2005, The Journal of clinical endocrinology and metabolism.

[17]  R. Czekay,et al.  The leptin receptor system of human platelets , 2005, Journal of thrombosis and haemostasis : JTH.

[18]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[19]  M. Buemi,et al.  Leptin-dependent platelet aggregation in healthy, overweight and obese subjects , 2003, International Journal of Obesity.

[20]  G. Davı̀,et al.  Platelet activation in obese women: role of inflammation and oxidant stress. , 2002, JAMA.

[21]  Kortelainen Ml.  Myocardial infarction and coronary pathology in severely obese people examined at autopsy. , 2002 .

[22]  S. Koschnick,et al.  Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. , 2001, The Journal of clinical investigation.

[23]  A. Yalçın,et al.  Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency. , 2001, Obesity research.

[24]  M. Nakata,et al.  Leptin promotes aggregation of human platelets via the long form of its receptor. , 1999, Diabetes.

[25]  R. Virmani,et al.  Sudden death as a result of heart disease in morbid obesity. , 1995, American heart journal.

[26]  M. Reilly,et al.  Cellular activation by thromboxane A2 and other eicosanoids. , 1993, European heart journal.

[27]  S. Chierchia,et al.  Pathophysiology of coronary occlusion in acute infarction. , 1986, Circulation.